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Oct1 and Gata3 Transcription Factors 
Differentially Bind NIH & Spretus in vitro 
Non-melanoma skin cancers (NMSC) are the most common forms of cancer in the 
world accounting for nearly half of all cancer diagnoses. Rates of NMSC are on the 
rise with an over 300% increase in diagnosis of these cancers in the last 20 years. 
While environmental risk factors for skin cancers are well understood, little is known 
about genetic risk factors for these cancers. Mouse linkage studies have identified 
several loci housing skin cancer susceptibility genes.  Human tumors show evidence 
of preferential allelic imbalance for polymorphisms in Hdac9, a gene mapping to one 
of the linkage regions, Skts5.  One intron in the Hdac9 gene between exons 8 and 9 
contains an enhancer for Twist1, affecting limb development and phenotypes in the 
skin. Twist1 is a known regulator of skin differentiation and has a documented role in 
cancer. The hypothesis of this study is that this enhancer locus plays a role in the 
differential risk for NMSC between the cancer susceptible NIH/Ola and cancer 
resistant Spretus/EiJ mice. Sequence analyses identified several polymorphisms 
between these strains in this intron which are predicted by in silico methods to disrupt 
transcription factor binding. To investigate in vitro effects of these variants, intron 
fragments from both NIH/Ola and Spret/EiJ murine DNA were cloned into an 
enhancer reporting PGL3 vector and transfected into both normal keratinocyte C5N 
and squamous cell carcinoma A5 cells. Luciferase assay and real-time PCR data 
suggest these variants are responsible for changes in gene expression, specifically in 
the Twist1 gene.  Chromatin Immunoprecipitation studies are being performed to test 
whether transcription factors, Oct1 and Gata3 that are predicted to differentially bind 
the NIH/Ola and Spret/EiJ enhancer , are involved in the differential Twist1 
expression. This project has the potential implication of discovering the role a specific 
gene locus, Skts5, plays in NMSC risk. 
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Intron Fragment # Broken Up By Custom Primers 
• Custom primers were designed to break up Hdac9 intron 8 into smaller 
fragments capable of being sequenced 
• In total, 43 polymorphisms were found between cancer susceptible NIH/Ola 
and cancer resistant Spretus mice DNA 
 
   We hypothesize that variants in the Hdac9 intron 8 Enhancer Locus play a role in the 
differential risk for Non-melanoma Skin Cancers observed between the cancer 
susceptible NIH/Ola and the cancer resistant Spretus mouse strains.  
    The Specific Aims of this project include the following: 
 
     1.  Determine if variants exist between NIH and Spretus DNA within Hdac9 intron 8.  
     2.  Identify and characterize any enhancer sites in the murine Hdac9 intron 8 sequence 
     3.  Determine which gene(s) are targets of the enhancer(s) and demonstrate via qPCR 
     4.  Identify specific transcription factor/DNA binding interactions potentially associated  
          with enhancer activity using Chromatin Immunoprecipitation Assays 
 
Spret 
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 Figure 1: A) Examples of sequence variants within Hdac9 intron 8 between NIH & Spret 
 B) Map of Hdac9 gene with Intron 8 magnified. Custom primer inserts shown visually.  
 Figure 2: Cells transfected with pGL3 + NIH Inserts 1 & 2 show significantly higher   
 Luciferin expression than those transfected with pGL3 + Spret Inserts 1 & 2 in both   
 C5N normal keratinocyte and A5 SCC cell lines. Insert 1: p<0.01**, Insert 2: p<0.05* 
• Enhancer activity exists in the Insert 1 & 2 region of Hdac9 Intron 8 
• This enhancer activity is unique to the NIH mouse strain, not found in Spretus 
• Enhancer activity does not extend to later portions of the intron (i.e. Insert 7) 
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   Figure 3: A) Real-Time PCR Data indicating cells transfected with pGL3+NIH Insert 1 
   display a near 2 fold increase in Twist1 expression compared to pGL3 control and  
   pGL3+Spretus Insert 1 in A5 cells (p<0.05). B) Map of proposed  genetic interaction 
• Twist1 identified as a target gene of the Hdac9 Intron 8 enhancer activity 
• Similar study looking at Hdac9 did not see significant differences in expression 
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Polymorphism 
  
 
 
Binding Strain 
  
 
 
Significance Score 
Oct1 ATATACACT C/G Spretus 89.7 
Gata3 AATCACG C/T NIH 85.9 
CdxA ATATAG G/C NIH 85.0 
Lyf-1 TGGGAT A/G Spretus 85.7 
Gfi-1 ATAGTTGTGAT A/G Spretus 85.9 
Nkx-2 TCAAGTG C/A Spretus 89.9 
AP-1 GTGATTAA A/G NIH 86.4 
   Table 1: In silico predictions of transcription factors that will differentially bind NIH  
   and Spretus DNA at the Hdac9 Enhancer locus. Databases utilized include TFsearch,  
   DBD, PROMO(Transfac) and TFSiteScan. Cutoff score of 85.0 used for significance.  
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ChIP: Oct1 Binding to Hdac9  
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ChIP: Gata3 Binding to Hdac9 
Figure 4: A) Quantification of ChIP results for Oct1 and Gata3 Transcription 
Factors (TF).  B) Gel images of ChIP results for the respective TFs (C5N cells)   
• Oct1 shown to preferentially bind NIH Insert 1 in comparison to Spretus Insert 1  
• Gata3 shown to preferentially bind Spretus Insert 1 in comparison to NIH Insert 1 
• Both in silico predictions validated through in vitro ChIP studies 
• Implications for these factors in the functionality of the Hdac9 enhancer  
 
A 
B 
HDAC9 TWIST1 
A B      Mouse Genetic Locus of Hdac9 & Twist1 
• An intronic enhancer in the Hdac9 gene was identified in mice 
• This intronic enhancer was shown to be present in cancer susceptible NIH/Ola mice 
but not in cancer resistant Spretus mice 
• A relation between this enhancer and Twist1 upregulation was demonstrated  
• Two transcription factors, Oct1 and Gata3, were shown to differentially bind one of 
the two mice DNA strains, suggesting a possible mechanism for SCC risk at Skts5 
• One of the first studies analyzing the role of intronic enhancers in skin cancer risk 
A B 
